Dosing began at Weill Cornell Medical Center in a Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS.

In people with benign MS, there is a loss of overall brain tissue but other parts of the brain may grow to help compensate for the damage, a study suggests.